Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


01 abril 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Differences in Neointimal Thickness Between the Adluminal and the Abluminal Sides of Malapposed and Side-Branch Struts in a Polylactide Bioresorbable ScaffoldEvidence In Vivo About the Abluminal Healing Process

Juan Luis Gutiérrez-Chico, MD, PhD; Frank Gijsen, MSc, PhD; Evelyn Regar, MD, PhD; Jolanda Wentzel, MSc, PhD; Bernard de Bruyne, MD, PhD; Leif Thuesen, MD; John Ormiston, MD; Dougal R. McClean, MD; Stephan Windecker, MD; Bernard Chevalier, MD; Dariusz Dudek, MD, PhD; Robert Whitbourn, MD; Salvatore Brugaletta, MD; Yoshinobu Onuma, MD; Patrick W. Serruys, MD, PhD

Objectives: The goal of this study was to describe the neointimal healing on the abluminal side (ABL) of malapposed (ISA) struts and nonapposed side-branch (NASB) struts in terms of coverage by optical coherence tomography (OCT) and in comparison with the adluminal side (ADL).

01 enero 2011

INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY. Delayed subtotal coronary obstruction after transapical aortic valve implantation

Marian Kukucka, Miralem Pasic, Stephan Dreysse, Roland Hetzer

We report on an obstruction of the left main coronary artery which occurred after completion of an uneventful transapical aortic valve implantation (TAVI) procedure. This delayed subtotal coronary obstruction was detected by routine final transesophageal echocardiographic examination. Emergency implantation of a coronary stent eliminated myocardial ischemia. This case demonstrated that coronary artery obstruction can occur not only during the TAVI procedure but also some time later. This finding reinforces the idea that these patients must also be carefully evaluated in the early post-procedure period. Interactive CardioVascular and Thoracic Surgery 12 (2011) 57–60. Copyright © 2011 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.

01 abril 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Risk Factors and Outcomes of Post-Procedure Heart Blocks After Transcatheter Device Closure of Perimembranous Ventricular Septal Defect

Rong Yang, MD; Xiang-Qing Kong, MD; Yan-Hui Sheng, MD; Lei Zhou, MD; Di Xu, MD; Yong-Hong Yong, MM; Wei Sun, MD; Hao Zhang, MD; Ke-Jiang Cao, MD

Objectives: The aim of this study was to analyze the risk factors and mid-term outcomes associated with post-procedure heart blocks (PPHBs) after transcatheter closure of perimembranous ventricular septal defect (pmVSD).

01 febrero 2012

SOCIEDADE BRASILEIRA DE CARDIOLOGIA. Oclusión Percutánea de la Orejuela Auricular Izquierda con el Amplatzer Cardiac Plug™ en Fibrilación Auricular

Márcio José Montenegro, Edgard Freitas Quintella, Aníbal Damonte, Hugo de Castro Sabino, Ricardo Zajdenverg, Gustavo Pinaud Laufer, Bernardo Amorim, André Pereira Duque Estrada, Cristian Paul Yugcha Armas, Aline Sterque

La fibrilación auricular está asociada a accidentes vasculares de origen embólico que frecuentemente resultan en muerte o invalidez. Siendo eficaz en la reducción de esos eventos, la anticoagulación posee varias limitaciones y viene siendo ampliamente subutilizada. Más de 90% de los trombos identificados en los portadores de fibrilación auricular sin enfermedad valvular se originan en la orejuela auricular izquierda, cuya oclusión es investigada como una alternativa a la anticoagulación. Arq Bras Cardiol 2012;98(2):143-150.

01 abril 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Maximal Hyperemia in the Assessment of Fractional Flow Reserve

Antonio Maria Leone, MD, PhD; Italo Porto, MD, PhD; Alberto Ranieri De Caterina, MD; Eloisa Basile, MD; Andrea Aurelio, MD; Andrea Gardi, MS; Dolores Russo, MS; Domenico Laezza, RVT; Giampaolo Niccoli, MD, PhD; Francesco Burzotta, MD, PhD; Carlo Trani, MD; Mario Attilio Mazzari, MD; Rocco Mongiardo, MD; Antonio Giuseppe Rebuzzi, MD; Filippo Crea, MD

Objectives: This study sought to compare increasing doses of intracoronary (IC) adenosine or IC sodium nitroprusside versus intravenous (IV) adenosine for fractional flow reserve (FFR) assessment.

01 septiembre 2009

JACC: CARDIOVASCULAR INTERVENTIONS. Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer

Joanna J. Wykrzykowska, MD; Patrick W. Serruys, MD, PhD; Yoshinobu Onuma, MD; Ton de Vries, MA; Gerrit-Anne van Es, PhD; Pawel Buszman, MD; Axel Linke, MD; Thomas Ischinger, MD; Volker Klauss, MD; Roberto Corti, MD; Franz Eberli, MD, PhD; William Wijns, MD; Marie-Claude Morice, MD; Carlo di Mario, MD, PhD; Robert Jan van Geuns, MD, PhD; Peter Juni, MD, PhD; Stephan Windecker, MD, PhD

Objectives: We assessed the impact of vessel size on outcomes of stenting with biolimus-eluting degradable polymer stent (BES) and sirolimus-eluting permanent polymer stent (SES) within a randomized multicenter trial (LEADERS).

01 noviembre 2011

LANCET: Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial

Giulio G Stefanini, Bindu Kalesan, Patrick W Serruys, Dik Heg, Pawel Buszman, Axel Linke, Thomas Ischinger, Volker Klauss, Franz Eberli, William Wijns, Marie-Claude Morice, Carlo Di Mario, Roberto Corti, Diethmar Antoni, Hae Y Sohn, Pedro Eerdmans, Gerrit-Anne van Es, Bernhard Meier, Stephan Windecker, Peter Jüni

Background: The eff ectiveness of durable polymer drug-eluting stents comes at the expense of delayed arterial healing and subsequent late adverse events such as stent thrombosis (ST). We report the 4 year follow-up of an assessment of biodegradable polymer-based drug-eluting stents, which aim to improve safety by avoiding the persistent infl ammatory stimulus of durable polymers

01 septiembre 2008

LANCET: Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

Stephan Windecker, Patrick W Serruys, Simon Wandel, Pawel Buszman, Stanislaw Trznadel, Axel Linke, Karsten Lenk, Thomas Ischinger, Volker Klauss, Franz Eberli, Roberto Corti, William Wijns, Marie-Claude Morice, Carlo di Mario, Simon Davies, Robert-Jan van Geuns, Pedro Eerdmans, Gerrit-Anne van Es, Bernhard Meier, Peter Jüni

Background: A novel stent platform eluting biolimus, a sirolimus analogue, from a biodegradable polymer showed promising results in preliminary studies. We compared the safety and effi cacy of a biolimus-eluting stent (with biodegradable polymer) with a sirolimus-eluting stent (with durable polymer).

26 febrero 2012

WJC. Percutaneous panvascular intervention in an unusual case of extensive atherosclerotic disease

Rajesh Vijayvergiya, Dheeraj Garg, Saroj K Sinha

Atherosclerosis is a systemic disease, which can have varied clinical presentation with involvement of multiple vascular beds. It is common to come across patients with concomitant coronary artery disease (CAD) and peripheral arterial disease (PAD), in whom panvascular revascularization is required. As they are high-risk patients with poor clinical outcome, their management requires a comprehensive multi-specialty approach. Following improvement in technical skills and hardware for percutaneous interventions in recent years, more complex lesions with adverse clinical situations can undergo intervention by a cardiologist/vascular interventionist. We hereby report a case with CAD and PAD, who underwent successful complex coronary and multiple peripheral interventions for his symptomatic disease. World J Cardiol 2012 February 26; 4(2): 48-53. Copyright © 2012 Baishideng. All rights reserved.

24 agosto 2010

CIRCULATION. Relationship Between Arterial and Fibrous Cap Remodeling A Serial Three-Vessel Intravascular Ultrasound and Optical Coherence Tomography Study

Ryotaro Yamada, MD, Hiroyuki Okura, MD, Teruyoshi Kume, MD, Ken Saito, MD, Yoshinori Miyamoto, MD, Koichiro Imai, MD, Tetsuo Tsuchiya, MD, Tomoko Maehama, MD, Noriko Okahashi, MD, Kikuko Obase, MD, Akihiro Hayashida, MD, Yoji Neishi, MD, Takahiro Kawamoto, MD; and Kiyoshi Yoshida, MD

Background —Positive arterial remodeling and thin fibrous cap are characteristics of rupture-prone or vulnerable plaque. The natural course of the fibrous cap thickness and the relationship between serial arterial remodeling and changes in fibrous cap thickness are unknown. Therefore, the purpose of this study was to evaluate the relationship between changes in fibrous cap thickness and arterial remodeling by using optical coherence tomography (OCT) and intravascular ultrasound (IVUS) during 6-month follow-up. Copyright © 2010. American Heart Association. All rights reserved. Print ISSN: 1941-7640. Online ISSN: 1941-7632

02 agosto 2011

CIRCULATION. Impact of Sirolimus-Eluting Stent Fracture on 4-Year Clinical Outcomes

Hisashi Umeda, MD, PhD, Tomoko Kawai, MD, Naoki Misumida, MD, Tomoyuki Ota, MD, Kazutaka Hayashi, MD, Mitsunori Iwase, MD, PhD, FACC, Hideo Izawa, MD, PhD, Shigeo Sugino, MD, Takeshi Shimizu, MD, PhD, Yasushi Takeichi, MD, PhD, Ryoji Ishiki, MD, PhD, Haruo Inagaki, MD, PhD, Yukio Ozaki, MD, PhD, FACC and Toyoaki Murohara, MD, PhD, FACC

Background—Although stent fracture (SF) after sirolimus-eluting stent (SES) implantation has been recognized as one of the predisposing factors of in-stent restenosis, it remains uncertain whether SF can increase the risk of major adverse cardiac events (MACE), especially beyond 1 year after SES implantation. The aim of this study was to assess the impact of SF relative to non-SF on 4-year clinical outcomes after treatment with SES of comparable unselected lesions. Copyright © 2011. American Heart Association. All rights reserved. Print ISSN: 1941-7640. Online ISSN: 1941-7632

13 noviembre 2011

EHJ. Secondary stroke prevention: patent foramen ovale, aortic plaque, and carotid stenosis

Bernhard Meier1, Benedikt Frank, Andreas Wahl1 and Hans C. Diener

Stroke is a devastating event and remains as the third leading cause of mortality and the most important cause of serious, long-term disability.1 Most strokes are of ischaemic origin. Atherosclerosis plays a causative role as do other factors that vary among countries, genders, lifestyles, and a number of well-documented risk factors. In the USA, it is estimated that almost 90% of the roughly 800 000 strokes per year are ischaemic.3 Cardioembolic reasons account for 19% and carotid disease for 15% of those. A patent foramen ovale (PFO) is per se not yet considered a primary cause for stroke. It is subsumed under the ∼40% labelled cryptogenic. This paper deals with the stroke causes that are easiest to document and treat in the sense of primary and secondary prevention. Published on behalf of the European Society of Cardiology. All rights reserved. Copyright The Author 2012.

14 abril 2011

ASWAN HEART CENTRE. Transcatheter aortic valve implantation. Role of imaging

Michael Gessat, Thomas Frauenfelder, Lukas Altwegg, Jürg Grünenfelder and Volkmar Falk

Transcatheter aortic valve implantation (T-AVI) has shown good results in high-risk patients with severe aortic stenosis. Throughout the whole process of T-AVI, different imaging modalities are indispensable. Preoperatively, multislice computed tomography, angiography and transesophageal echo (TEE) are utilized for patient selection, valve selection, approach selection and the planning of implant placement. Intraoperatively, angiography and TEE are used for controlling placement of the guidewire and valve positioning. Quality control and follow-up require TEE imaging and can require additional CT or angiography studies. In the first half of this paper, we discuss the applicability of different imaging modalities for T-AVI in the light of the current best practice. Copyright 2010 Gessat et al, licensee Bloomsbury Qatar Foundation Journals. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial license CC BY-NC 3.0 which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.